search
Back to results

Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response

Primary Purpose

Post Operative Pain, Acute

Status
Recruiting
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Dexamethasone 24 mg
Placebo
Sponsored by
Vejle Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post Operative Pain, Acute focused on measuring Dexamethason, repeat, glucocorticoids, TKA surgery, steroids, High Pain Responders, postoperative pain, repeat dosing, FAST-TRACK

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 40 years.
  • Primary unilateral TKA.
  • Ability to participate in the study (understand written and spoken Danish language, self-reported pain and satisfaction).
  • Signed written informed consent form.
  • PCS >20.
  • Moderate to severe postoperative pain (VAS >30) in a 5-meter walk test 22-26 hours after end of surgery.

Exclusion Criteria:

  • Ongoing treatment of systemic glucocorticoids or other immunosuppressant treatment apart from inhaled steroids.
  • Insulin-dependent diabetes.
  • Pregnancy or breastfeeding.*
  • Allergies concerning the study-drug.
  • Mental disability that could impair a patient's decision-making capability of giving informed consent and not enabling valid data collection.
  • Patients with known diagnoses of schizophrenia, ongoing psychosis, bipolar disease and/or a history of ongoing anti-psychotic treatment.
  • Patients with modulated pain-reception (experience) based on other diseases or injuries, e.g. spinal cord or brain injury, severe polyneuropathies or neurologic disorders.
  • Peripheral nerve block per- or postoperatively.

    • Pregnancy: No women with suspected or proven pregnancy are eligible for inclusion. The following will be considered as safe contraception: intrauterine device or hormonal contraception. For women aged between 40-50 years, a urine HCG test for pregnancy will be performed.

Sites / Locations

  • Vejle Hospital. Orthopedic Surgery Department. Clinical Research UnitRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo tablet on day 1 after surgery given as one single dose.

Dexamethasone 24 mg on day 1 after surgery given as one single dose.

Arm Description

Control Group (CG): Intervention: Postoperative oral placebo tablet on day 1 after surgery given as one single dose.

Repeat Dose Group (RDG): Intervention: Postoperative oral dexamethasone 24 mg on day 1 after surgery given as one single dose.

Outcomes

Primary Outcome Measures

Postoperative pain after 48 hours / day 2 morning, according to VAS-scale
The amount of patients with moderate postoperative pain in a 5 meter walk test day 2 morgning(48 hours) postoperatively after total knee-arthroplasty. Pain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm.

Secondary Outcome Measures

Cumulated pain upon ambulation, according to VAS-scale (0-100mm), in a 5-meter walk test
Pain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm
Cumulated pain score, according to VAS-scale (0-100mm), at rest, upon ambulation in a 5-meter walk test and at night according to VAS-scale(0-100mm)
Pain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm
Quality of sleep, lethargy, dizziness, and nausea postoperative registration, according to the VAS-scale(0-100mm)
ain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm
Cumulative use of rescue analgesics per day.
Patient satisfaction with analgesic regimen in a ordinal scale from 0 to 10
Number of re-admissions within 30 days, and reasons why (follow-up by EPJ on postoperative day 30)
Morbidity and mortality (30-day follow-up by EPJ or telephone).
Number of participant with morbidity and mortality in the first 30 days. Follow-up by EPJ or telephone.
Why still in hospital, an audit into the reasons the patient has not yet been discharged from the ward
An investigation into reason of why our patients remain in the hospital in the days after total Knee Arthroplasty in our Fast-Track center. This is investigated through a questionnaire previously used in a similar investigation in our center. The questionnaire is filled in by our project nurse. the questionnaire is a checkmark schedule with predetermined reasons to stay in hospital like low bloodpressure, sedation, dizzyness, lack of physiotherapy and medical and surgical complications. The outcome assesment will be descriptive.

Full Information

First Posted
September 16, 2022
Last Updated
September 5, 2023
Sponsor
Vejle Hospital
Collaborators
Hvidovre University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05563155
Brief Title
Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response
Official Title
Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response - A Randomized Double-blind Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
July 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vejle Hospital
Collaborators
Hvidovre University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to compare the effect of a repeat moderate dose of glucocorticoids postoperatively after preoperative high dose upon postoperative pain after Total Knee Arthroplasty (TKA) in an High Pain Respondes (HPR) population to a standard single high dose systemic preoperative administration in an HPR population. As a standard procedure, all patients referred to the outpatient clinic due to suspected degenerative knee disease will be asked to fulfill the Pain Catastrophizing Scale (PCS). If TKA is decided, patients with a PCS score above 20 will be treated with intravenously administered Dexamethasone 1 mg/kg as a rounded-up-dose to closest 10 mg according to our guideline for FAST-TRACK TKA. The repeat-dosing group (RDG) will receive a dose of 24 mg dexamethasone tablets at 9-11 pm on the first postoperative day. The control-group (CG) will receive placebo tablets at 9-11 pm on the first postoperative day.
Detailed Description
Total hip and knee arthroplasty (THA/TKA) are frequently performed procedures and are expected to increase in numbers along with the growing elderly population the next decade. Total Knee Arthroplasty (TKA) is suitable for FAST-TRACK surgery, and is often performed as outpatient surgery with no hospital overnight stay. Challenges in FAST-TRACK surgery include postoperative pain, nausea and vomiting (PONV), complications due to rescue-analgesics and surgical complications. Pain is a well-known clinical problem, with up to 75% of TKA patients experiencing moderate to severe pain the first day after surgery, and 30-40% still experiencing moderate to severe pain 2 weeks after surgery, potentially delaying ambulation and recovery within the first weeks. The role of severe acute postoperative pain upon the development of chronic pain is debatable, but important. Data from our recently finished study in High Pain Responders (HPR), defined as patients with a score above 20 on the Pain Catastrophizing Scale (PCS), receiving preoperative high dose dexamethasone (Nielsen et al.: IN PREPARATION, clinicaltrials.gov ID NCT03763734, EudraCT 2018-002635-23, VEK H-18034778) found a persistent moderate to severe pain in 40 % of patients, at time 48 hours after surgery, corresponding to the time when the physiological effect of our dexamethasone intervention declines. Moderate to severe pain (Visual analogue scale (VAS >30)) 24 hours postoperatively during a 5-meter walk test was associated with relapse pain at 48 hours. Other studies have made attempts of investigating the effect of a repeated dose of steroids after TKA and Total Hip Arthroplasty (THA), but all have done so with a postoperative injection of low dose steroids. No previous studies have, to our knowledge, investigated the effects of repeat dosing after a preoperative high dose of steroid, and none focused on patients selected by their postoperative pain response. In spite of many studies and systematic reviews on the subject, the optimal timing and dose for steroid-intervention in TKA in different patient groups is still inadequately understood The study conduct with a repeat moderate dose of steroids given as an oral tablet at 9-11 pm on the day after TKA surgery in patients receiving preoperative high dose steroids, who have a high postoperative pain response, in a FAST-TRACK perioperative setting. Oral administration of the repeat dose will allow for possible early discharge in future clinical settings. The hypothesis is that a repeat moderate dose of glucocorticoid will reduce the postoperative pain on postoperative day 2 and cumulated pain day 2-3 after TKA surgery, when compared to single high dose preoperatively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Operative Pain, Acute
Keywords
Dexamethason, repeat, glucocorticoids, TKA surgery, steroids, High Pain Responders, postoperative pain, repeat dosing, FAST-TRACK

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
A double-blind randomization will be carried out, 5:5 block-randomization, half of which will be allocated to the CG and the other half to RDG. Group 1: Postoperative placebo tablet on day 1 after surgery. Group 2: Postoperative dexamethasone 24 mg tablet on day 1 after surgery.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Blinding The patient, all personnel attending in treatment and care of the patient, the investigators and the sponsor will all be blinded to the study-drug allocation, until all data processing is finished. The randomization-sequence will be stored in a sealed envelope at the Pharmacy at Lillebaelt Hospital who carried out the packaging-process. The randomization personnel have no contact to the patient.
Allocation
Randomized
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo tablet on day 1 after surgery given as one single dose.
Arm Type
Placebo Comparator
Arm Description
Control Group (CG): Intervention: Postoperative oral placebo tablet on day 1 after surgery given as one single dose.
Arm Title
Dexamethasone 24 mg on day 1 after surgery given as one single dose.
Arm Type
Active Comparator
Arm Description
Repeat Dose Group (RDG): Intervention: Postoperative oral dexamethasone 24 mg on day 1 after surgery given as one single dose.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone 24 mg
Other Intervention Name(s)
Dexa-ratiopharm
Intervention Description
Dexamethasone 24 mg on day 1 after surgery.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablet given on day 1 after surgery.
Primary Outcome Measure Information:
Title
Postoperative pain after 48 hours / day 2 morning, according to VAS-scale
Description
The amount of patients with moderate postoperative pain in a 5 meter walk test day 2 morgning(48 hours) postoperatively after total knee-arthroplasty. Pain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm.
Time Frame
Day 2 morning
Secondary Outcome Measure Information:
Title
Cumulated pain upon ambulation, according to VAS-scale (0-100mm), in a 5-meter walk test
Description
Pain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm
Time Frame
From day 2-3
Title
Cumulated pain score, according to VAS-scale (0-100mm), at rest, upon ambulation in a 5-meter walk test and at night according to VAS-scale(0-100mm)
Description
Pain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm
Time Frame
From day 2-7
Title
Quality of sleep, lethargy, dizziness, and nausea postoperative registration, according to the VAS-scale(0-100mm)
Description
ain is monitored by the Visual Analog Scale(VAS) 0-100 mm, where 0 is no pain and 100 mm is the worst pain. Moderate pain is considered a VAS >30 mm
Time Frame
From day 2-7
Title
Cumulative use of rescue analgesics per day.
Time Frame
From day 2-7
Title
Patient satisfaction with analgesic regimen in a ordinal scale from 0 to 10
Time Frame
Day 7
Title
Number of re-admissions within 30 days, and reasons why (follow-up by EPJ on postoperative day 30)
Time Frame
Day 30
Title
Morbidity and mortality (30-day follow-up by EPJ or telephone).
Description
Number of participant with morbidity and mortality in the first 30 days. Follow-up by EPJ or telephone.
Time Frame
Day 30
Title
Why still in hospital, an audit into the reasons the patient has not yet been discharged from the ward
Description
An investigation into reason of why our patients remain in the hospital in the days after total Knee Arthroplasty in our Fast-Track center. This is investigated through a questionnaire previously used in a similar investigation in our center. The questionnaire is filled in by our project nurse. the questionnaire is a checkmark schedule with predetermined reasons to stay in hospital like low bloodpressure, sedation, dizzyness, lack of physiotherapy and medical and surgical complications. The outcome assesment will be descriptive.
Time Frame
Day 7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 40 years. Primary unilateral TKA. Ability to participate in the study (understand written and spoken Danish language, self-reported pain and satisfaction). Signed written informed consent form. PCS >20. Moderate to severe postoperative pain (VAS >30) in a 5-meter walk test 22-26 hours after end of surgery. Exclusion Criteria: Ongoing treatment of systemic glucocorticoids or other immunosuppressant treatment apart from inhaled steroids. Insulin-dependent diabetes. Pregnancy or breastfeeding.* Allergies concerning the study-drug. Mental disability that could impair a patient's decision-making capability of giving informed consent and not enabling valid data collection. Patients with known diagnoses of schizophrenia, ongoing psychosis, bipolar disease and/or a history of ongoing anti-psychotic treatment. Patients with modulated pain-reception (experience) based on other diseases or injuries, e.g. spinal cord or brain injury, severe polyneuropathies or neurologic disorders. Peripheral nerve block per- or postoperatively. Pregnancy: No women with suspected or proven pregnancy are eligible for inclusion. The following will be considered as safe contraception: intrauterine device or hormonal contraception. For women aged between 40-50 years, a urine HCG test for pregnancy will be performed.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Claus Varnum, Doctor
Phone
+45 79405779
Email
claus.varnum@rsyd.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Anders Deichmann Springborg, Doctor
Phone
+45 4049 9097
Email
anders.deichmann.springborg.01@regionh.dk
Facility Information:
Facility Name
Vejle Hospital. Orthopedic Surgery Department. Clinical Research Unit
City
Vejle
ZIP/Postal Code
7100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claus Varnum, Doctor. PhD.
Phone
+45 79405779
Email
claus.varnum@rsyd.dk
First Name & Middle Initial & Last Name & Degree
Anders Deichmann Springborg, Doctor, PhD student
Phone
+45 4049 9097
Email
anders.deichmann.springborg.01@regionh.dk

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Yes The individual patient data will be made available in anonymized form.
IPD Sharing Time Frame
Data will be available from the date of publication
Citations:
PubMed Identifier
29783896
Citation
Pabinger C, Lothaller H, Portner N, Geissler A. Projections of hip arthroplasty in OECD countries up to 2050. Hip Int. 2018 Sep;28(5):498-506. doi: 10.1177/1120700018757940. Epub 2018 May 21.
Results Reference
background
PubMed Identifier
31606338
Citation
Erivan R, Villatte G, Dartus J, Reina N, Descamps S, Boisgard S. Progression and projection for hip surgery in France, 2008-2070: Epidemiologic study with trend and projection analysis. Orthop Traumatol Surg Res. 2019 Nov;105(7):1227-1235. doi: 10.1016/j.otsr.2019.07.021. Epub 2019 Oct 9.
Results Reference
background
PubMed Identifier
30293141
Citation
Romanini E, Decarolis F, Luzi I, Zanoli G, Venosa M, Laricchiuta P, Carrani E, Torre M. Total knee arthroplasty in Italy: reflections from the last fifteen years and projections for the next thirty. Int Orthop. 2019 Jan;43(1):133-138. doi: 10.1007/s00264-018-4165-7. Epub 2018 Oct 6.
Results Reference
background
PubMed Identifier
30180053
Citation
Sloan M, Premkumar A, Sheth NP. Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460. doi: 10.2106/JBJS.17.01617.
Results Reference
background
PubMed Identifier
28426262
Citation
Gromov K, Kjaersgaard-Andersen P, Revald P, Kehlet H, Husted H. Feasibility of outpatient total hip and knee arthroplasty in unselected patients. Acta Orthop. 2017 Oct;88(5):516-521. doi: 10.1080/17453674.2017.1314158. Epub 2017 Apr 20.
Results Reference
background
PubMed Identifier
23973139
Citation
Chan EY, Blyth FM, Nairn L, Fransen M. Acute postoperative pain following hospital discharge after total knee arthroplasty. Osteoarthritis Cartilage. 2013 Sep;21(9):1257-63. doi: 10.1016/j.joca.2013.06.011.
Results Reference
background
PubMed Identifier
19413820
Citation
Andersen LO, Gaarn-Larsen L, Kristensen BB, Husted H, Otte KS, Kehlet H. Subacute pain and function after fast-track hip and knee arthroplasty. Anaesthesia. 2009 May;64(5):508-13. doi: 10.1111/j.1365-2044.2008.05831.x.
Results Reference
background
PubMed Identifier
28134653
Citation
Lavand'homme P. Transition from acute to chronic pain after surgery. Pain. 2017 Apr;158 Suppl 1:S50-S54. doi: 10.1097/j.pain.0000000000000809. No abstract available.
Results Reference
background
PubMed Identifier
24258688
Citation
Lavand'homme PM, Grosu I, France MN, Thienpont E. Pain trajectories identify patients at risk of persistent pain after knee arthroplasty: an observational study. Clin Orthop Relat Res. 2014 May;472(5):1409-15. doi: 10.1007/s11999-013-3389-5.
Results Reference
background
PubMed Identifier
16698416
Citation
Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. doi: 10.1016/S0140-6736(06)68700-X.
Results Reference
background
Citation
Sullivan M, Bishop S, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995; 7: 524-32
Results Reference
background
PubMed Identifier
20832052
Citation
Khan RS, Ahmed K, Blakeway E, Skapinakis P, Nihoyannopoulos L, Macleod K, Sevdalis N, Ashrafian H, Platt M, Darzi A, Athanasiou T. Catastrophizing: a predictive factor for postoperative pain. Am J Surg. 2011 Jan;201(1):122-31. doi: 10.1016/j.amjsurg.2010.02.007. Epub 2010 Sep 15.
Results Reference
background
PubMed Identifier
30033064
Citation
Xu H, Zhang S, Xie J, Lei Y, Cao G, Pei F. Multiple Doses of Perioperative Dexamethasone Further Improve Clinical Outcomes After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Study. J Arthroplasty. 2018 Nov;33(11):3448-3454. doi: 10.1016/j.arth.2018.06.031. Epub 2018 Jul 4.
Results Reference
background
PubMed Identifier
29514368
Citation
Li D, Zhao J, Yang Z, Kang P, Shen B, Pei F. Multiple Low Doses of Intravenous Corticosteroids to Improve Early Rehabilitation in Total Knee Arthroplasty: A Randomized Clinical Trial. J Knee Surg. 2019 Feb;32(2):171-179. doi: 10.1055/s-0038-1636506. Epub 2018 Mar 7.
Results Reference
background
PubMed Identifier
28474088
Citation
Xu B, Ma J, Huang Q, Huang ZY, Zhang SY, Pei FX. Two doses of low-dose perioperative dexamethasone improve the clinical outcome after total knee arthroplasty: a randomized controlled study. Knee Surg Sports Traumatol Arthrosc. 2018 May;26(5):1549-1556. doi: 10.1007/s00167-017-4506-x. Epub 2017 May 4. Erratum In: Knee Surg Sports Traumatol Arthrosc. 2017 Jun 19;:
Results Reference
background
PubMed Identifier
30078660
Citation
Dissanayake R, Du HN, Robertson IK, Ogden K, Wiltshire K, Mulford JS. Does Dexamethasone Reduce Hospital Readiness for Discharge, Pain, Nausea, and Early Patient Satisfaction in Hip and Knee Arthroplasty? A Randomized, Controlled Trial. J Arthroplasty. 2018 Nov;33(11):3429-3436. doi: 10.1016/j.arth.2018.07.013. Epub 2018 Jul 19.
Results Reference
background
PubMed Identifier
31563397
Citation
Kim JK, Ro DH, Lee HJ, Park JY, Han HS, Lee MC. Efficacy of Systemic Steroid Use Given One Day After Total Knee Arthroplasty for Pain and Nausea: A Randomized Controlled Study. J Arthroplasty. 2020 Jan;35(1):69-75. doi: 10.1016/j.arth.2019.08.026. Epub 2019 Aug 19.
Results Reference
background
PubMed Identifier
28647788
Citation
Lei YT, Xu B, Xie XW, Xie JW, Huang Q, Pei FX. The efficacy and safety of two low-dose peri-operative dexamethasone on pain and recovery following total hip arthroplasty: a randomized controlled trial. Int Orthop. 2018 Mar;42(3):499-505. doi: 10.1007/s00264-017-3537-8. Epub 2017 Jun 25.
Results Reference
background
PubMed Identifier
29258763
Citation
Lei Y, Huang Q, Xu B, Zhang S, Cao G, Pei F. Multiple Low-Dose Dexamethasone Further Improves Clinical Outcomes Following Total Hip Arthroplasty. J Arthroplasty. 2018 May;33(5):1426-1431. doi: 10.1016/j.arth.2017.11.057. Epub 2017 Dec 5.
Results Reference
background
PubMed Identifier
31802486
Citation
Kehlet H, Joshi GP. The systematic review/meta-analysis epidemic: a tale of glucocorticoid therapy in total knee arthroplasty. Anaesthesia. 2020 Jul;75(7):856-860. doi: 10.1111/anae.14946. Epub 2019 Dec 4. No abstract available.
Results Reference
background
PubMed Identifier
19585177
Citation
Riddle DL, Wade JB, Jiranek WA, Kong X. Preoperative pain catastrophizing predicts pain outcome after knee arthroplasty. Clin Orthop Relat Res. 2010 Mar;468(3):798-806. doi: 10.1007/s11999-009-0963-y. Epub 2009 Jul 8.
Results Reference
background
PubMed Identifier
27922839
Citation
Toner AJ, Ganeshanathan V, Chan MT, Ho KM, Corcoran TB. Safety of Perioperative Glucocorticoids in Elective Noncardiac Surgery: A Systematic Review and Meta-analysis. Anesthesiology. 2017 Feb;126(2):234-248. doi: 10.1097/ALN.0000000000001466.
Results Reference
background
PubMed Identifier
28854533
Citation
Jorgensen CC, Pitter FT, Kehlet H; Lundbeck Foundation Center for Fast-track Hip and Knee Replacement Collaborative Group. Safety aspects of preoperative high-dose glucocorticoid in primary total knee replacement. Br J Anaesth. 2017 Aug 1;119(2):267-275. doi: 10.1093/bja/aex190.
Results Reference
background
PubMed Identifier
25115430
Citation
de la Motte L, Kehlet H, Vogt K, Nielsen CH, Groenvall JB, Nielsen HB, Andersen A, Schroeder TV, Lonn L. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. Ann Surg. 2014 Sep;260(3):540-8; discussion 548-9. doi: 10.1097/SLA.0000000000000895.
Results Reference
background
PubMed Identifier
12202852
Citation
Carter R, Holiday DB, Grothues C, Nwasuruba C, Stocks J, Tiep B. Criterion validity of the Duke Activity Status Index for assessing functional capacity in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2002 Jul-Aug;22(4):298-308. doi: 10.1097/00008483-200207000-00014.
Results Reference
background
PubMed Identifier
32168057
Citation
Rupp M, Lau E, Kurtz SM, Alt V. Projections of Primary TKA and THA in Germany From 2016 Through 2040. Clin Orthop Relat Res. 2020 Jul;478(7):1622-1633. doi: 10.1097/CORR.0000000000001214.
Results Reference
result

Learn more about this trial

Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response

We'll reach out to this number within 24 hrs